Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients.

[1]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2015, The Cochrane database of systematic reviews.

[2]  G. Kaplan,et al.  Budesonide for induction of remission in Crohn's disease. , 2015, The Cochrane database of systematic reviews.

[3]  Y. Barenholz,et al.  Enhanced Transferrin Receptor Expression by Proinflammatory Cytokines in Enterocytes as a Means for Local Delivery of Drugs to Inflamed Gut Mucosa , 2011, PloS one.

[4]  M. Kappelman,et al.  Nonmelanoma skin cancer in inflammatory bowel disease: A review , 2011, Inflammatory bowel diseases.

[5]  G. Dalmasso,et al.  Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon. , 2011, Biomaterials.

[6]  J. Söderholm,et al.  Importance of disrupted intestinal barrier in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[7]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[8]  C. Lehr,et al.  A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro. , 2010, Molecular pharmaceutics.

[9]  A. Lamprecht.  IBD: Selective nanoparticle adhesion can enhance colitis therapy , 2010, Nature Reviews Gastroenterology &Hepatology.

[10]  J. Sanderson,et al.  Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.

[11]  G. Dalmasso,et al.  Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. , 2010, Gastroenterology.

[12]  M. Thabane,et al.  Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[13]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[14]  Y. Barenholz,et al.  Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. , 2009, Molecular pharmaceutics.

[15]  S. Zeissig,et al.  High‐Resolution Analysis of Barrier Function , 2009, Annals of the New York Academy of Sciences.

[16]  Alf Lamprecht,et al.  The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. , 2008, Biomaterials.

[17]  W. Bemelman,et al.  European evidence-based Consensus on the management of ulcerative colitis: Current management. , 2008, Journal of Crohn's & colitis.

[18]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer , 2008, Clinical Cancer Research.

[19]  M. Zeitz,et al.  Mechanisms of epithelial translocation of the α2-gliadin-33mer in coeliac sprue , 2008, Gut.

[20]  A. Lamprecht,et al.  5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[21]  A. Lamprecht,et al.  Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[22]  I. Cascorbi,et al.  A clinical trial on absorption and N‐acetylation of oral and rectal mesalazine , 2007, European journal of clinical investigation.

[23]  A. Lamprecht,et al.  Nanoparticles made of fluorescence-labelled Poly(L-lactide-co-glycolide): preparation, stability, and biocompatibility. , 2006, Journal of nanoscience and nanotechnology.

[24]  U Wahnschaffe,et al.  Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease , 2006, Gut.

[25]  A. Lamprecht,et al.  Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. , 2006, International journal of pharmaceutics.

[26]  Y. Kawashima,et al.  A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[27]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[28]  Y. Barenholz,et al.  Differential Adhesion of Normal and Inflamed Rat Colonic Mucosa by Charged Liposomes , 2004, Pharmaceutical Research.

[29]  Hirofumi Takeuchi,et al.  Size-Dependency of DL-Lactide/Glycolide Copolymer Particulates for Intra-Articular Delivery System on Phagocytosis in Rat Synovium , 2002, Pharmaceutical Research.

[30]  Y. Kawashima,et al.  Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. , 2001, The Journal of pharmacology and experimental therapeutics.

[31]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[32]  Claus-Michael Lehr,et al.  Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa , 2001, Pharmaceutical Research.

[33]  C. Lehr,et al.  Lectin-mediated drug delivery: the second generation of bioadhesives. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[34]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.